ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Lenalidomide

Also written as “lenalidomide”, “CC-5013” and “Drug: Carfilzomib + Lenalidomide + Dexamethasone”.

Its studies are mostly in Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Myelodysplastic Syndromes · Lymphoma, Non-Hodgkin · Lymphoma, Mantle-Cell, led by 6 companies.

Drug pageLenalidomide: every studyMany companies study it; this page follows only the 78 they lead. All 751 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 5, 200378 company-led studies, 3 open or runningNext primary completion: May 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only670 open or runningphase 3since Mar 5, 2003Aug 16, 2002none ahead
Takeda50 open or runningphase 4since May 30, 2017Jul 25, 2007none ahead
Oncotherapeuticsits history only32 open or runningphase 2since Jul 30, 2014Jul 30, 2014none ahead
bionor-immuno-asits history only10 open or runningphase 2since Sep 11, 2012Sep 11, 2012none ahead
Samyang Biopharmaceuticalsits history only10 open or runningphase 1since Jun 25, 2017Jun 25, 2017none ahead
starton-therapeutics-incits history only11 open or runningphase 2since Sep 20, 2023Sep 20, 2023May 31, 2027phase 2 · NCT06087653

Also a collaborator on its studies: AbbVie, Prologue Research International, Karyopharm Therapeutics, Incyte, Johnson & Johnson, Abbott, ICON Clinical Research and Hoffmann-La Roche.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 25, 2007First study: phase 2 study in Multiple MyelomaFirst studyNCT00507442 · 158 enrolled · United States
  2. Sep 22, 2016Phase 2 study in Relapsed and/or Refractory Multiple MyelomaNCT02917941 · 34 enrolled · Japan
  3. May 30, 2017Phase 4 study in Multiple MyelomaNCT03173092 · 141 enrolled · United States
  4. Jan 23, 2018Phase 4 study in Relapsed and/or Refractory Multiple MyelomaNCT03416374 · 45 enrolled · Japan
  5. Dec 20, 2021Phase 4 study in Multiple MyelomaNCT05183139

TargetBeta

“CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
pomalidomideruleBristol-Myers Squibbphase 451

Studies

All 5 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05183139Multiple Myeloma4WithdrawnDec 31, 20260
NCT03416374Relapsed and/or Refractory Multiple Myeloma · Japan4CompletedMay 28, 202145
NCT03173092Multiple Myeloma · United States4TerminatedMar 30, 2026141
NCT02917941Relapsed and/or Refractory Multiple Myeloma · Japan2CompletedAug 31, 201934
NCT00507442Multiple Myeloma · United States2CompletedOct 2010158

How it is read

Names in the registry

  • “Lenalidomide”, 67 entries
  • “lenalidomide”, 16 entries
  • “CC-5013”, 14 entries
  • “Drug: Carfilzomib + Lenalidomide + Dexamethasone”, 1 entry
  • “Tafasitamab plus lenalidomide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.